In vitro and in vivo potency of insulin analogues designed for clinical use.
about
Insulin and analogue effects on protein degradation in different cell types. Dissociation between binding and activity.Insulin aspart: a new rapid-acting insulin analog.Insulin analogues: have they changed insulin treatment and improved glycaemic control?Optical nanosensor architecture for cell-signaling molecules using DNA aptamer-coated carbon nanotubes.Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD miceDifferences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years.Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice.Characterization of the functional insulin binding epitopes of the full-length insulin receptor.Positron emission tomography detection of human endothelial cell and fibroblast monolayers: effect of pretreament and cell density on 18FDG uptake.Antigen-based immune therapeutics for type 1 diabetes: magic bullets or ordinary blanks?Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding.Insights in regulated bioanalysis of human insulin and insulin analogs by immunoanalytical methods.Assay-dependent variability of serum insulin concentrations: a comparison of eight assays.Increase in hepatic and decrease in peripheral insulin clearance characterize abnormal temporal patterns of serum insulin in diabetic subjects.
P2860
Q33928096-66E3FAA6-AC3A-4B52-9528-0C2CF90F979BQ34122518-019BAE77-456A-4827-A595-C944D9BFC9C8Q34580951-AB3C939A-9C18-4F0A-BF44-755AE1A0A4ABQ35228643-A6B19902-F119-425E-BA42-565B0EC85F6DQ37193406-B0E3FE91-C7A5-4077-99FA-EF5D8136143CQ37372373-249EF044-08C4-45F4-BB47-B2DFC36A7E04Q38255407-51DD7FA8-7EDF-48C7-8116-1D9E48463AB3Q38813347-112DD40D-6CD4-497B-ACF0-E29B804187AEQ40440929-87BD4349-42AB-4567-8D19-7AF5E47B5433Q42092020-81C62633-E4B2-4345-81CD-2278F197579EQ42739489-89035DDB-0358-46D3-A660-6C11716699DAQ42993498-C619F8F3-6C61-46EB-ADBD-B1048435566DQ43893344-21347266-BCC5-45E9-B94A-8A8E1710964AQ51273075-7599FFFB-A3D8-4CDA-94EB-4A10B276D578Q55263317-DF8A9F32-719F-440A-835E-46FC26AFE26C
P2860
In vitro and in vivo potency of insulin analogues designed for clinical use.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
In vitro and in vivo potency of insulin analogues designed for clinical use.
@en
type
label
In vitro and in vivo potency of insulin analogues designed for clinical use.
@en
prefLabel
In vitro and in vivo potency of insulin analogues designed for clinical use.
@en
P2093
P1433
P1476
In vitro and in vivo potency of insulin analogues designed for clinical use.
@en
P2093
Markussen J
Schlichtkrull J
Sørensen AR
P304
P356
10.1111/J.1464-5491.1991.TB02122.X
P577
1991-11-01T00:00:00Z